These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28393726)

  • 61. Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
    Lopes RD; Thomas L; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Friend K; Mardekian J; Pan X; Yuce H; Jones WS
    Am J Cardiol; 2021 Jun; 148():69-77. PubMed ID: 33667438
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.
    Kongnakorn T; Lanitis T; Annemans L; Thijs V; Goethals M; Marbaix S; Wautrecht JC
    Clin Drug Investig; 2015 Feb; 35(2):109-19. PubMed ID: 25511639
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding.
    Ray WA; Chung CP; Murray KT; Smalley WE; Daugherty JR; Dupont WD; Stein CM
    JAMA; 2018 Dec; 320(21):2221-2230. PubMed ID: 30512099
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
    Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection.
    Yoshio T; Tomida H; Iwasaki R; Horiuchi Y; Omae M; Ishiyama A; Hirasawa T; Yamamoto Y; Tsuchida T; Fujisaki J; Yamada T; Mita E; Ninomiya T; Michitaka K; Igarashi M
    Dig Endosc; 2017 Sep; 29(6):686-694. PubMed ID: 28295638
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
    Lawal OD; Aronow HD; Shobayo F; Hume AL; Taveira TH; Matson KL; Zhang Y; Wen X
    Circulation; 2023 Mar; 147(10):782-794. PubMed ID: 36762560
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
    Dhamane AD; Ferri M; Keshishian A; Russ C; Atreja N; Gutierrez C; Emir B; Yuce H; Di Fusco M
    Adv Ther; 2023 Mar; 40(3):887-902. PubMed ID: 36527598
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
    López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
    BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
    [No Abstract]   [Full Text] [Related]  

  • 73. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
    Wisløff T; Hagen G; Klemp M
    Pharmacoeconomics; 2014 Jun; 32(6):601-12. PubMed ID: 24715603
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
    Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK
    Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
    Gourzoulidis G; Kourlaba G; Kakisis J; Matsagkas M; Giannakoulas G; Gourgoulianis KI; Vassilakopoulos T; Maniadakis N
    Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
    Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
    J Thromb Haemost; 2016 May; 14(5):1043-53. PubMed ID: 26924677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.